LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Smith & Nephew PLC ADR

Geschlossen

32.62 0.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.53

Max

32.93

Schlüsselkennzahlen

By Trading Economics

Einkommen

100M

296M

Verkäufe

4.7M

3B

KGV

Branchendurchschnitt

28.777

76.798

Dividendenrendite

2.36

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

6.5M

723M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+9.86% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.36%

2.37%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

207M

14B

Vorheriger Eröffnungskurs

32.44

Vorheriger Schlusskurs

32.62

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Dez. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. Dez. 2025, 23:51 UTC

Ergebnisse

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. Dez. 2025, 23:39 UTC

Wichtige Markttreiber

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. Dez. 2025, 21:40 UTC

Ergebnisse

Nike Sales Tick Up, But China Weakness Persists

18. Dez. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. Dez. 2025, 23:37 UTC

Market Talk
Ergebnisse

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. Dez. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. Dez. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. Dez. 2025, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. Dez. 2025, 22:58 UTC

Akquisitionen, Fusionen, Übernahmen

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. Dez. 2025, 22:56 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. Dez. 2025, 22:55 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:59 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Dez. 2025, 21:35 UTC

Ergebnisse

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. Dez. 2025, 21:31 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev Down 17% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q EPS 53c >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Apparel Rev $3.91B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Equipment Rev $550M >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q N Amer Rev $5.63B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Footwear Rev $7.66B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev $1.42B >NKE

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

9.86% Vorteil

12-Monats-Prognose

Durchschnitt 35.75 USD  9.86%

Hoch 37.5 USD

Tief 34 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat